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Polygenic tests such as genome-wide small nucleotide polymorphism (SNP) risk testing, 
exome or genome sequencing are currently on the horizon for genetic testing for inherited 
cancer risk. We are unsure of how patients would accept this future genetic testing and 
the best way to fully understand the experience of undergoing a polygenic test for breast 
cancer risk is to explore the experience of women who have already undergone the 
process. In Ontario, these individuals are those who have already had gene panel testing 
(GPT). This group’s opinions and experiences will be directly related to the refinement 
and modification of the existing GPT process and will provide guidance for polygenic 
testing offered in the future. Methods: Fourteen women who have undergone GPT in the 
past year were interviewed in a semi-structured manner regarding their GPT experience. 
Interviews were recorded and transcribed, then qualitatively coded to identify key words, 
phrases, and expressed concepts surrounding GPT. Results: Participants had an overall 
favourable opinion regarding their GPT experience, with minor changes to be considered 
in future provision of GPT. In general, GPT appears to be well-tolerated within the 
context of a traditional genetics assessment and participants that did not receive a 
clinically significant result through GPT felt that they would be open to pursuing other 
forms of genetic testing in the future such as polygenic testing, despite the possibility of 
receiving an uncertain result. 







Gene panel testing refers to the concurrent sequencing of a predetermined set of 
genes via a next-generation sequencing technology. In recent years, several commercial 
genetic testing labs and academic institutions have introduced gene panel tests. Cancer 
risk panels usually include cancer-predisposition genes that have a high and/or moderate 
penetrance. High penetrance genes confer a lifetime cancer risk of anywhere from 
seventy to one hundred percent (i.e. BRCA1, BRCA2, TP53, etc.), while moderate 
penetrance genes confer a lifetime cancer risk of anywhere from thirty to sixty percent 
(i.e. CHEK2, ATM, PALB2, etc.).   
 There are many advantages to gene panel testing when compared to sequential 
single-gene testing, a practice which was only recently made obsolete by the introduction 
of gene panel testing. Firstly, panel tests are typically found to lower the cost of 
sequencing per gene. In other words, customers are receiving more for their money. With 
panel testing, there is also the potential to identify patients who have mutations co-
occurring in different genes, potentially impacting their healthcare management. In 
regards to clinical efficiency, there is a quicker turnaround time for panel testing versus 
sequential genetic testing, which may also impact the patient’s healthcare management or 
decision-making process. There is also less hassle for the patient and provider since 
informed consent can be performed all at once instead of each consecutive time a new 
test is ordered. With gene panel testing there may be improved detection of mutations in 
patients with abnormal cancer phenotypes, absent family history data, a family history 
that does not meet testing criteria, or when the family history meets criteria for several 
inherited cancer predisposition syndromes. Lastly, many genetic testing companies have 
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flexibility in what they offer on their panels, such that clinicians may add or subtract 
certain genes from the panel according to their preferences and the patient’s needs (Hall 
et al., 2014).     
 Conversely, there are some drawbacks to panel testing. First, incidental findings 
may often arise when administering a panel test, either in addition to or instead of a 
mutation that explains the patient’s phenotype. Particularly in the field of cancer genetics, 
incidental findings can cause challenges when mutations are found in genes where there 
is limited or no data regarding medical management. This is specifically relevant for 
moderate penetrance genes in which expression may be also be influenced by external 
factors such as the environment (Hall et. al., 2014). Patients receiving uncertain 
information regarding genetic risk information and clinical management may find this 
information difficult to accept (Hiraki et al., 2014). Additionally, with the increased 
number of genes now available on panel tests comes an increased prevalence of variants 
of unknown significance (VUSes). These VUSes can often be misinterpreted by the 
provider and/or patient as a true pathogenic mutation that is causing the patient’s or their 
family’s phenotype. This can lead to erroneous risk management recommendations by the 
provider. This is particularly troubling when we acknowledge that over time, the majority 
of VUSes are classified as a benign variation in the patient’s genetic code (Hall et al., 
2010). A small fraction of VUSes will be reclassified to pathogenic, and relaying this 
data to the patients often requires time and manpower.  
 Equivalent rates of BRCA1/2 mutations and BRCA1/2 VUSes are found in 
patients that have solely BRCA1/2 testing versus those that have gene panel testing. Gene 
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panel testing increases diagnostic yield and increases the rate of VUS findings (Kapoor et 
al., 2015; Buys et al., 2017). Approximately half of individuals who test positive for a 
non-BRCA mutation receive cancer screening and prevention recommendations that are 
altered from management that was previously determine solely from their family history 
(Desmond et al., 2015).  
 Collectively, these findings highlight not only the efficacy of gene panels at 
identifying BRCA mutations, but also the impact that identification of non-BRCA 
mutations has on diagnostic yield and patient care.  
Breast Cancer Genetic Testing: The Decision to Test 
 One of the biggest initial questions after the introduction of BRCA1/2 genetic 
testing was regarding patients’ motivations for testing. Women who undergo BRCA1/2 
testing are at a higher risk of being carriers for a BRCA1 mutation, are more likely to be 
Ashkenazi Jewish, are more likely to have a known family mutation, are more likely to 
want ovarian cancer risk information for themselves, and are more likely to want breast 
and ovarian cancer risk information for family members. They are also less likely to be 
worried about insurance or job discrimination (Armstrong et al., 2000).  
  Research by Augestad et al. (2016) on women who were newly diagnosed with 
breast or ovarian cancer and who had been offered and accepted genetic testing found 
that patients are overwhelmed with the amount of information regarding all things breast 
cancer-related. Patients indicated that they need support and counselling from a 
healthcare professional in order to assist their decision-making process. Researchers 
believe that the ability to obtain such services might enable women to improve their 
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ability to sort through emotions and comprehend the overwhelming details of their breast 
cancer and genetic testing experience.  
Psychosocial Implications of Cancer Panel Gene Testing 
 Unaffected individuals with a family history of hereditary breast and ovarian 
cancer who receive positive genetic testing results are most considerably affected by 
intrusive thoughts and feelings of avoidance and distress. Additionally, genetic testing-
specific stress is generally increased in patients that are of a lower age, of African-
American race, of lower education level, of lower genetic knowledge, or of Hispanic 
origin (Lumish et al., 2017). 
Cancer Genetic Testing in Ontario 
 In Canada, women who have personal or family histories consistent with a 
hereditary breast or ovarian cancer syndrome may be referred for genetic counselling and 
genetic testing, which are available through the socialized health care system.  The 
Ministry of Health and Long Term Care has published a set of guidelines for individuals 
in the province of Ontario who should be offered genetic counseling and who are eligible 
for genetic testing. These guidelines base recommendations on the individual’s personal 
and/or familial cancer history (Genetic counseling eligibility, UHN).  Genetic testing for 
BRCA1/2 was introduced to Ontarians in 2001 and since then over 30,000 individuals 
have been tested (Finch et al., 2015). However, only in the past two to three years have 
Ontario genetics clinics begun utilizing gene panel testing (GPT).  
Understanding GPT and Possible Future Testing Options 
Currently, additional testing methods are being developed to provide a more 
thorough look at inherited cancer risk by using polygenic tests such as genome-wide 
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small nucleotide polymorphism (SNP) risk testing, or exome and genome sequencing. 
The best way to fully understand the process and experience of undergoing a polygenic 
test for breast cancer risk is to explore the experience of women who have already 
undergone the process. In Ontario, these individuals are those who have already had 
GPT. This group’s knowledge, opinions and experiences will be directly related to the 
refinement and modification of the existing GPT process. Additionally, it will provide 
guidance for future polygenic testing that may be offered in the future.   
As previously mentioned, GPT has been introduced to many high risk cancer 
genetics clinics in Ontario within the past couple of years. As we know, many of the 
genes included on GPT panels can lead to results of uncertain significance or positive 
results in moderate-risk genes and thus may have uncertain clinical management 
implications. We are unsure of how patients would accept future genetic testing or how 
they would utilize the information resulting from it. Given the complexity of themes 
surrounding the GPT process, qualitative analysis would be ideal for exploring patient’s 
opinions and preferences surrounding the introduction of this future genetic testing 
method in Ontario. In addition, these explorations will also inform the provision of 
possible future polygenic tests for breast cancer susceptibility. Furthermore, concepts and 





  This study aims to explore the opinions, preferences, understanding, and 
psychological/health behavior impacts of gene panel testing for individuals that received 
genetic counseling and genetic testing for breast cancer risk. Additionally, this study aims 
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to explore opinions regarding the provision of a future hypothetical polygenic breast 
cancer risk test. The protocol for this study was developed by Gord Glendon, MSc of the 
Lunenfeld-Tanenbaum Research Institute and Mount Sinai Hospital, Mount Sinai Health 
System (MSH).  
Participants 
 A chart review of all female patients who had undergone breast cancer gene panel 
testing (GPT) at the Marvelle Koffler Breast Center at MSH was performed to identify 
eligible participants. Eligible participants were considered to be those who had their 
results session within a year of the study invitation date and who were fluent in the 
English language. Ineligible participants included women who were actively undergoing 
cancer treatment or who were not fluent in the English language. Eligible participants 
were mailed an invitation letter, a study consent form, and a stamped return envelope. 
Individuals who returned completed consent forms were contacted via phone to set up a 
time for a taped qualitative telephone interview. Individuals who did not return a consent 
form were re-contacted by telephone within an approximate three-week period to 
determine if the invitation arrived and to address any questions the invitee might have.  
Purposive sampling was attempted to ensure that the study included participants that were 
both affected and unaffected by breast cancer and had received both clinically 
informative and uninformative results.  There was a total of fourteen participants. The 
demographics of the study participants are shown in Appendix 1.  
Interview 
 The study team previously created a list of pertinent issues to be discussed in a 
semi-structured interview. These issues were developed and refined into interview 
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questions. The interview guide comprised of questions that aimed to understand the 
participants’ GPT experience, impacts of GPT, opinions and preferences regarding the 
provision of GPT, as well as participants’ opinion regarding the provision of a future 
polygenic test. The following is an example of an interview question and related prompts: 
‘Do you feel that the GPT helped to explain your personal or family history of breast 
cancer? Do you feel the GPT added any information beyond what you may have learned 
from your BRCA1/2 test? Do you feel that this test added anything to your understanding 
of your cancer / your family’s cancer / your breast cancer risk?’ Participants were 
encouraged to bring up additional topics related to GPT that they wanted to discuss. No 
additional topics came up during the course of the interviews that would have 
considerably altered the interview guides. Each interview was conducted by Gord 
Glendon, Angelina Tryon, or both. Interview questions may be found in the Appendix. 
Data Analysis 
 The interviews were transcribed verbatim and the transcripts were read closely by 
the interviewing team to facilitate the coding process. Transcription quality was ensured 
by comparing the interview audio with the transcribed text for 4 randomly selected 
interviews. The development of codes took place in joint reviews after each interview by 
the interviewing team, which facilitated the complete set of themes and sub-themes that 
made up the majority of the study findings. The codes and themes were elucidated in this 
fashion. Coding was able to identify key words, phrases, and expressed concepts 






Genetic Testing  
 
 All genetic testing was performed at MSH. All participants received the same 
gene panel test, comprised of the following genes which confer for increased lifetime 
risks of breast and/or ovarian cancer: BRCA1, BRCA2, CDH1, EPCAM, MLH1, MSH2, 
MSH6, PALB2, PMS2, PTEN, STK11, TP53, ATM, BRIP1, CHEK2, RAD51C, RAD51D, 
BARD1, FANCC, NBN. Each panel included both Next-Generation Sequencing and 
deletion/duplication analysis. 
IRB Approval 
 This study was approved by the Mount Sinai Hospital Research Ethics Board on 
June 14, 2017 and was approved for expedited review by the Sarah Lawrence College 
Institutional Review Board.  
 
Results 
Understanding the Participants’ GPT Experience: Timeline and Testing 
 When asked about motivations behind pursuing GPT, participants indicated a 
variety of reasons. The majority of participants indicated that they wished to pursue GPT 
because it had been recommended by their physician and because pursuing GPT would 
satisfy their information-seeking behaviours. One participant noted, ‘Dr X was in the 
Mount Sinai clinic the day I had the appointment. And he went over things with me, 
recommended that under the circumstances genetic screening would be useful and 
brought in [GC X] while I was still there…Now I'm single and adopted, I have no genetic 
information. So this was extra useful. Not that I have any kids to warn but just for my 
own peace of mind’. Other participants indicated that the reason for pursuing testing was 
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for the sake of their children or other family members. One participant stated, ‘And I 
know that was one of the decisions – or one of the factors that impacted on my decision 
to do the gene testing, was whether it could have any relevance for other family members 
who might, depending on my results, then need to go through gene testing themselves, if 
they so wished’. Additional reasons for pursuing GPT included that it would allow the 
participants to make decisions regarding treatment of their breast cancer or decisions 
regarding cancer screening.    
 Participants displayed an overall good understanding of the GPT test. The 
majority of participants explicitly acknowledged that they knew GPT was different than a 
BRCA1/2 genetic test in that it looked at more than two genes. Some participants even 
correctly recalled that the GPT looked at 20 genes specifically. One participant stated, 
‘… it's a screening for 20 particular genes that they know cause -where they know 
mutations can cause an increased risk of cancer. And from what I know it can tell you 
you have an increased risk of cancer, it doesn’t tell you you'll definitely get it or if you 
don’t test positively for the genes that you won't get it. It's just people who do test 
positive for genes like BRCA 1 or 2 tend to have a much, much higher incident of breast 
cancer and therefore there's also special preventative measure that they can take if they 
find that they have the gene, so, yeah and so it's just, as far as I understand, just looking 
whether you fit into your particularly high risk group or not’. At least half of participants 
expressed that they knew that GPT results can have impacts on cancer recurrence risk and 
risk of future cancers. More than half of participants also explicitly understood that 
different genes on the panel can have different impacts in regards to types of cancers that 
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a person may be at risk for. Two participants even acknowledged that this test may have 
implications for obtaining insurance in the future.  
 All participants had their GPT results delivered over the phone, by a genetic 
counsellor. Most participants who tested negative did not come for an in-person follow-
up appointment in additional to the initial results phone call. Some participants indicated 
that they preferred phone results, given that the process is quicker than coming for a 
results appointment. One participant was glad that her results were delivered over the 
phone, but did emphasize that results might be best delivered based on patient preference. 
She noted, ‘…it was quicker, it was, you know, done quickly, you had an opportunity to 
process it in your own way …What I might suggest and I don’t know, but I might suggest 
giving the person an option, you know, "Would you prefer that we - that the result is 
shared with you over the phone or would you prefer to come down and have an 
appointment?" [Interviewer: Mm-hmm, yeah it might help accommodate those people 
who-] Yes, who need a face-to-face, they need more explanation, they - you know that 
kind of thing. Now obviously if that had come back positive, you know she had indicated 
to me she would like to have a follow-up appointment’.  
 Some participants recalled the entire process from genetics consultation up until 
results disclosure to be around two months, while other participants recalled this process 
taking as long as five months. Several participants indicated that they wished the process 
had taken less time, with a minority even specifying that they had some anxiety during 
the waiting period for results. One woman stated, ‘You know, I was a bit anxious during 
that time period. I wouldn't say it super negatively affected my quality of life particularly 
because I'm just anxious in general. And so it's not that much of a difference. But yeah, 
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the long waiting period was a bit nerve wracking in some ways. In other ways though it 
was, like okay really I have to wait to make this decision and I'd rather have the 
information sooner rather than later when it comes down to that’. On the other hand, a 
couple of participants did not think much about the test or possible results during the 
waiting period. One woman noted, ‘Yeah, whatever it was I had no investment, I 
obviously wanted it to be a negative but, I mean, I…forgot about it and… then I got the 
results’.  
Impacts of GPT for Participants 
 Overall, participants affected by breast cancer displayed an accurate 
understanding of what their GPT results meant in regards to their personal history of 
breast cancer. One participant who tested negative and when speaking about her previous 
cancer diagnosis stated, ‘So, it's not genetic it looks like. So, it's just the luck of the draw 
and I will just keep an eye on things because there is the possibility that as genetic testing 
improves and they find more related genes, there will be more information forthcoming’. 
However, one participant affected by breast cancer and who tested positive for a CHEK2 
gene mutation displayed incorrect understanding regarding her test results and what that 
meant in regards to her breast cancer diagnosis. She stated, ‘…the cancer I've got isn't 
genetic…Breast cancer is not, you know, a genetic … disorder or I don't have a genetic 
predisposition for it or anything like that. It's just one of those things’. Generally, 
participants affected and unaffected by breast cancer understood the meaning of their 
GPT results in relation to their family history and their future risk of breast cancer. One 
unaffected participant who tested negative noted, ‘I didn’t have any of the mutations and 
so now it's just I'm part of the high risk screening program because of my family history’. 
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A minority (2) of participants displayed uncertainty or incorrect knowledge in regards to 
the meaning of negative test results. One participant, when asked what the results mean in 
regards to her risk for breast cancer stated, ‘I don’t have a risk, or my genes say I don’t 
have a risk at all actually’, and when asked about whether she thought her risk for cancer 
was either at or above population risk, she stated, ‘I don’t know maybe population risk, I 
don’t know’. Furthermore, several participants had a general understanding as to whether 
their results would or would not have implications for family members. One participant 
affected with breast cancer, who tested negative with one VUS in ATM stated, ‘…the 
results are relevant to, like I said before, family members who now, you know, don’t 
necessarily need to undergo genetic testing, because it doesn’t look like I can carry a 
family-based gene. So that suggested others don’t necessarily need to undergo testing 
immediately, or at any point necessarily, although they will be eligible for advanced 
screening methods as in my own diagnosis’.  
 A majority of participants who tested negative or received a VUS result did not 
feel as though the GPT explained their personal or family history of breast cancer. One 
affected participant noted, ‘So for me, it did not, because I don’t have a family history of 
breast cancer. I am very young. You know, statistically speaking, I should not have breast 
cancer. And so this couldn’t clear things up for us, it just made it more of a mystery’. 
Another affected participant explained, ‘…it still leaves the unanswered question right 
because I mean I'm a very fit person, I breastfed each of my kids for two years, I never 
took the pill, all of those things that medically are supposed to put a woman at higher risk 
were not the case for me, so that kind of leaves the big question mark 'well why'…’. A 
third affected participant, though her results were negative, indicated that these results 
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may have inspired her to pursue reconnecting with her biological family since she was 
adopted at birth, ‘…it eliminated some possibilities, the hereditary possibilities. I always 
wondered but I've never followed up on looking for my biological family…And this 
might have triggered that search’. A majority of participants who tested negative felt that 
their GPT results gave the peace of mind. One woman stated, ‘…certain genes, if they 
come back positive, it also increases your breast – or suggests that you're at higher risk 
for getting ovarian cancer. You know, I certainly don’t want any other kinds of cancer. 
So in that sense, knowing that I don’t have any genes, means that I'm not, as far as we 
know, predisposed to getting ovarian cancer, so that was a huge relief for me’. Another 
woman noted, ‘Well - no I feel much, much better and I feel that, you know, it's an 
answer to a fear that I had and the thing is that I did decide to have a child even though 
with this big thing weighing on my mind that this child - that I may pass on this illness or 
disease to him and his future family, and so knowing that he's not a carrier has just - it 
has lifted a huge worry off my shoulder…’ Additionally, participants that tested positive 
for a gene mutation as a result worried more about their breast cancer risk or risk for 
other cancers. One participant affected by breast cancer who tested positive for an ATM 
mutation stated, ‘I'm just a little worried about a couple of the other cancers I can get 
because there's nothing they can do about them. You can't test for them’.  
 Participants with VUS results were asked whether they felt any feelings of 
uncertainty in regards to these types of ambiguous results. One individual stated that she 
felt her VUS results gave her some anxiety. She stated, ‘It gives me a little bit of anxiety 
and for sure, I have it in mind, what does that mean. I know I cannot do anything, and 
this might take years before we understand what exactly that is. And maybe in the future 
	 16 
you'll find something that might help us understand that’. On the other hand, another 
participant stated that the VUS result didn’t make her feel anxious. She noted, ‘How do I 
feel, not too...not too badly. I mean I'm not really that concerned about this. I mean I said 
… I wanted to have the genetic testing and I said, "As far I'm concerned the more 
information the better", and so yeah I don't - it doesn't make me anxious or anything … 
I'm not ignoring it … you know it’s unclear whether this possible variant changes 
anything, I don't think so as far as I'm concerned moving forward’. A third participant 
related the uncertainty of GPT results to inherent uncertainty in life. She said, ‘I have 
discovered that life is uncertain, really. Yeah at this point in my life I'm much better at 
taking it as it comes. [Interviewer: Right. So you were willing to undertake a little bit of 
uncertainty in your sort of quest to understand better what was going on. Is that kind of a 
good summary?] Yes. That pretty well sums it up, yes’. One woman also made a point to 
say that she thought clinics should take responsibility for recontacting patients regarding 
VUSes. She stated, ‘Yeah it’s probably not the greatest system just to sort of leave it up 
to me to contact her but, you know, it is what it is. 
…I think it might be better system to have the clinic contact the person but I'm prepared 
to diarize it’. 
 All participants who were asked about whether they shared their test results with 
family and friends admitted that they were open about their testing process and results 
with either select friends and family or all friends and family.  One participant was 
particularly open about her testing process and results, ‘Oh yeah, yes I - my whole family 
knows about it and...yes and I have a sister too so she's well aware of what's happened 
and the results of it and everything. Yeah and I've told my friends as well, you know, 
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because it’s good news right [laughs] that I don't have any of the genes, so yes I shared it 
with everyone in my life actually’. Another participant who tested positive for a BRCA2 
mutation was a bit more reserved with telling anyone outside of her aunts and husband. 
She noted, ‘Yeah, I don't know. I just wasn't comfortable telling them yet. I don't know 
why. It's one of those weird things I'm not quite sure. I think because I want to figure out 
what I'm going to do about it first before people ask me what my plan is’.  
 The majority of participants explicitly expressed their knowledge of what actions 
and/or medical screening were recommended by their medical team based on their GPT 
results. One affected participant who received a VUS result stated, ‘… if it had come 
back positive…I would probably have said, okay, I’m going to --- double mastectomy, 
and I’m certain that would have been the recommendation of my doctors as well… So 
that certainly has impacted on that decision, and again, my doctors as well, because now 
their recommendation is only to do a single, whereas if the results had been different, 
they would have said do a double. So it certainly impacted on me in that sense’. An 
unaffected participant who tested negative also stated, ‘… I got a phone call from my 
genetic counsellor and … she was going to refer me because of my family history to the 
high risk screening program but that there wouldn’t be any other steps that we needed to 
take’. On the other hand, an affected participant who tested positive for a CHEK2 
mutation recalled being told that she would need to make an appointment for a 
colonoscopy, but when asked whether she would need more frequent colonoscopies than 
other people her age, she stated, ‘I have no idea’. 
 Participants were also asked about health behaviour changes post-GPT return of 
results. Two participants expressed that they would change their health behaviour such as 
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diet and/or exercise based on their GPT results. A participant affected by breast cancer 
who tested negative stated, ‘Well the thing is that the test results I feel like they are 
backing-up, you know, my diagnosis of breast cancer, so once I was diagnosed with 
breast cancer it's like I'm forced to change everything about my diet, you know my 
activity level, everything, even my mental wellbeing right, emotional and everything…I 
think that the genetic test results are like complimentary to it where it says to you, "You 
know what, you don't have this gene, you don’t have any of these genes", so look at the 
environment factors, look at your diet, look at all these other things’. One participant was 
unsure about whether the results would change her health behaviours, while several 
participants indicated that they would not change health behaviours based on their results. 
One unaffected participant, when asked whether the result would change her health 
behaviour replied, ‘No, no. I mean it's always good to stay positive and proactive about 
your health regardless’. Another participant, affected with breast cancer who tested 
positive for a CHEK2 mutation stated that ‘…Most of the changes have been made 
simply because of the triple negative [breast cancer]’. Some participants indicated that 
they would change their cancer screening based on GPT results, with one participant who 
tested positive for a CHEK2 mutation indicating, ‘… in terms of impact that's about the 
only thing - for me it was to say, okay, we'll make an appointment to have a 
colonoscopy’. A participant who tested positive for a BRCA2 mutation also indicated, ‘… 
in a week I had MRI and a mammogram booked. Already. Like done. She had those 
booked for me within a week for my breasts. And so I went down there. So that whole 
week was very - like stressful because all of a sudden I'm going for these test, one right 
after the other. And then I have two appointments coming up in February’. Other 
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participants indicated they would not be changing their cancer screening habits either due 
to personal preference or due to doctor’s recommendation. One unaffected participant 
who tested negative stated, ‘No, I'll just have my routine screenings like I usually do and 
that's it. It'll stay the same just to be on the safe side even though it says no but it's always 
good to keep checking’. 
 
Opinions and Preferences on the Provision of GPT 
 Participants were retrospectively asked about their understanding of what their 
possible GPT results could have been (ie. positive, negative, and/or VUS). Several 
participants felt they understood what the possible test results could be, with some 
participants even identifying possible results as being either positive, negative, or VUS. 
One woman explained, ‘… there’s the positive and there’s the negative, and then there’s 
the ones where they’re unsure, or something like that. Yeah, that was a little like “Okay, 
well what do you do with that information” that I guess sounded like . . . I don’t know. I 
think the way it sounded was that they would continue to have developments in research 
and somehow – I don’t know, someday that would make sense. I don’t know, I can’t 
recall, I just know that there was one that was like the one answer to the testing that was 
like inconclusive kind of’. Conversely, one participant did not feel as though she 
understood much about possible test results, She stated, ‘…at the time I thought I told her 
[the genetic counsellor] that I had a science background so I kind of understood a little bit 
but… I realize that I don't really understand very much about this’. Most participants 
recalled that at the time of the genetics appointment, they felt they had a good 
understanding of what kind of clinical recommendation could be gleaned from test 
results, with one woman affected with breast cancer stating, ‘Yes she was very clear 
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about that, she talked about if the test negative, you know, obviously I didn't - wouldn't 
have had the X gene, if the test was positive she said she'd like me to come back and talk 
about the possibility of a hysterectomy and I said well that's kind of down the road, I 
have not made that decision yet but I really appreciated her kind of saying that, you 
know, rather than just, "Here's your result, see you later, good luck", you know, that she 
said she would like to see me again for a follow-up appointment for sure and, you know; 
so that was - she kind of gave the scenario for one and two, option one and two’. On the 
other hand, one unaffected woman who tested positive for a BRCA2 mutation noted, ‘…I 
knew that if it comes back positive that they're going to tell me you have a risk for this or 
a risk for that… what I didn't expect was, like, the discussion of, like, so fast that you 
have to - you should do this now and you should do this, and be thinking about this, this, 
and this type of thing. About different surgeries. Like I just felt like wow, that was - just a 
lot to think about. I knew - I expected different - like I expected if she said you're positive 
with this gene that you're going to get this - this is what you're at risk for. Yes. I 
did. [Interviewer: Do you feel like you had a good understanding of what possible 
clinical recommendations could be made based on the results] No, that's what I would say 
no’.  
 
 Most participants indicated they would not change anything in regards to their 
preparation or pre-test counselling for the GPT.  One participant stated, ‘Yeah, so I mean, 
for the most part the experience, you know, was really well-managed and, almost – to use 
your previous word – positive. You know, it’s a very complicated thing to explain to 
people who have no knowledge whatsoever of genetics, and so we were given some 
really useful resources and things that were pretty – you know, some very informative 
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information that was pretty clearly spelled-out’. Another participant wished she had been 
given information in advance of what a genetic test was, ‘The information of what is a 
genetic test, maybe to give you some information before you go to the test itself, and 
what are they. Maybe provide some more information. …It could be printed, it could be 
online, some additional information or reference to some websites that you link to, 
maybe. Or just a quick handout, you know, a handout with simple information, but put 
everything plain and simple…’ Alternatively, another participant wished she had been 
given a handout after the appointment, ‘I think I would have liked to have gotten a little 
bit more information on paper about the tests themselves just because it would have 
saved me some excessive Googling after the appointment’. One woman indicated that the 
information went over her head, ‘So yeah, so she had explained about, you know, how 
the genes fit into the DNA sequence, but I didn’t really understand that….And it wasn’t 
really practical in terms of assisting me in my decision-making process, but she did 
explain how things kind of all fit in, etcetera’. 
 Several participants indicated that they would not change how results were 
returned or anything about the patient letter. However, some participants took issue with 
the complexity of information presented in the patient letter. One woman noted, ‘… I 
received the results, and I received the papers and there’s so much information that it’s … 
I cannot understand it. It’s just the experts will decipher that thing, because it’s like a 
code, you know what I mean? It doesn’t make any difference to me to have all these 
pages printed with its code and information I cannot understand. So just put it plain and 
simple, and keep the rest for yourself. I mean, the technicians need that information, 
that’s fine for them, I don’t need it’. Another participant agreed and would have preferred 
	 22 
a patient letter in layman’s terms, ‘The only thing I would say is that the results were not 
as clearly spelled-out as the initial information. So you know, they have, like, really – 
you know, some good diagrams and explanations and stuff done to explain why would 
you undergo genetic testing. And then we did get full results after the fact, which was 
great – I'm really happy to have them, because those full results are definitely more 
technical in their write-up, there’s not really the layman’s version of them’. A couple of 
participants also had thoughts on receiving results that have no clear implications for risk 
or management. One woman explained, ‘…if it's not clear it just freaks people out’, while 
another stated, ‘… I don't know if that would just make you more crazy. I don't know, I 
can't answer that because I think that depends on the person’. 
 Participants had an overall favourable opinion regarding their GPT experience, 
with many going as far as to recommend this test to others in a similar situation. One 
participant noted, ‘You know overall I was impressed by the process. I hadn’t had too 
much experience with this kind of program in the health system in Ontario particularly. 
I'm a relatively young, healthy woman so I didn’t have too much reason to. And overall it 
was a positive experience. I think it was helpful. And certainly all the staff I worked with 
and everyone I talked to has been really professional and explaining things at a level 
that's not, you know requiring an MD which I always appreciate. So it's been a good 
experience’. One participant affected with breast cancer stated, ‘…it was a good 
experience, it wasn’t a traumatising experience or anything like that, it was really a very 
simple process. And when you have cancer, you're already going through so … it’s like 
the easiest part of it. So why not, really?’ Another participant noted, ‘…I'm from Mexico. 
So this is something that in, in Mexico, the women that have had breast cancer in my 
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family, and I had a choice to receive this type of genetic test. I mean, I believe that we 
have a privilege here in Canada to have this option, and for sure, I would recommend it to 
my friends’. However, many participants indicated that the decision to pursue GPT may 
depend on the individual and their particular situation. A participant commented, ‘… I 
love the idea that knowledge is power but I also understand that if you’re not in the right 
state of mind to deal with this it could actually force you to put your head in the sand and 
not want to deal with it…if you’re in a negative state of mind, if you’re depressed or 
whatever, this is not the right time for you to get the results right; but if you’re in a 
position where you're like fight or flight type of mode where you're like, "My health is in 
jeopardy I need to do something about it"; so I think that that will empower you to move 
forward in the steps of deciding, you know, what's best for you…’ 
Future Polygenic Testing 
 Participants who tested negative or received VUS results via GPT were asked 
their opinion on whether they would be interested in pursing future polygenic testing that 
would look at SNPs or thousands of genes across the genome. This testing would help 
participants try and understand how cancer runs in families. Participants indicated that 
they would be motivated to pursue this future polygenic testing. Several of these 
participants indicated that they would be motivated to pursue this testing in order to find 
answers that GPT did not give them. When asked why she would be motivated to pursue 
future testing, one unaffected participant who had negative GPT results noted, ‘I would 
say just because for me I - and particularly going through this process I just realized it 
was much more comforting to me to think about having the information even if it wasn’t 
the results I wanted or it wasn’t - or if it was something that was serious about my health. 
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To me that's better than finding out five years after I could have been diagnosed that I 
suddenly have cancer, you know. And I've seen that happen to a lot of women over my 
life and that's not - you know, as much as I can avoid that kind of medical surprise I 
would prefer to’. 
 Participants were also asked about their willingness to pursue this future testing, 
given the possibility of receiving uncertain results as with GPT. Participants seemed 
fairly alright with this possibility, with some willing to risk the possibility of receiving 
uncertain results if it meant there was a chance they could get an answer. One affected 
participant who tested negative stated, ‘I mean, really, like, you already have uncertainty, 
right. From my perspective, you don’t know what’s in your genes, but whatever is there, 
is already there, there’s nothing you can do about it. So getting any more uncertainty, 
like, doesn’t change anything, right, you're already in that position where you don’t 
know, so … And if you get results that are meaningful, then it gives you something that 
you can take action on’. Again, another participant commented that this uncertainty may 
not be for everyone, ‘I will tell you, I think it will cause more anxiety and not everybody 
might handle that type of information very well, but in my case, I would like to know it 
and start preparing’. 
 Participants were asked whether they would pursue this future testing if it could 
also provide information regarding risks for other diseases aside from cancer, even 
diseases that do not have treatment or medical screening available.  Many individuals 
were also interested in pursuing this testing, however many acknowledged the 
psychological difficulties that may come with learning this information. One participant 
noted, ‘No, no, I would like to know about any other disease that I could have in the 
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future. Whereas I know it’s important, what are the worst things that I could deal in the 
future…but just the fact that you know it, might change some decisions that I take now or 
in the future. It’s something that will probably cause me anxiety, yes, but I still want to 
know’. Another participant said, ‘Yeah, you know, I think I would probably ultimately 
decide that I wanted to know. But I think finding out something about a disease that has 
not really been in my consciousness or in my family history would really, would be a bit 
more of a psychological difficulty to take I guess. Like I would find that bit more of like 
oh, I'm worried about breast cancer but actually I'm going to get Alzheimer's…’ One 
participant also highlighted that medical screening may not be the only way to ‘prevent’ 
disease. She said, ‘…it depends on how you define what you can do about it. There's 
spiritual ways and… there are physical and medical ways and social ways…I think that 
there are all these things that can be done, depends on how you define that’. One 
participant was not interested in learning about risks for other diseases at this point in 
time, ‘When it comes to testing, you know, my probabilities for every disease under the 
sun, I think, you know, there’s certainly an aspect that appeals to me. Like I said, having 
that information you can ---, you can take action. But I mean, at the moment I'm certainly 
not in a position where I would want to do that, because I have enough to deal with, right. 
Like, I don’t need to know that I'm also at risk of getting Alzheimer’s and whatever else 
they would test…’.  
 In regards to the provision of this future polygenic test, participants had varied 
opinions. A few participants brought up the point of having this test provided with the 
context of a hospital system or specialty breast clinic. One participant admitted, ‘I also 
feel strongly that you deal with one hospital system and stick with it and everything you 
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do – as I joke I say I go to X for all my cancers. But, you know, it's not such a joke, I 
think that it really is, I like to go to the hospital, I like to go to the same hospital each 
time so they have everything from whatever I'm dealing with…They're able to coordinate 
everything all in one…’. Another participant stated, ‘… I think the best one ideally would 
be to a breast, like clinic, because they have people who are experienced working in it 
versus – like I like my GP but I mean some people don’t have a GP so they’d go through 
like a walk-in clinic. I don’t know. So, ideally it would be better to be in an environment 
where they work with breast cancer on a regular basis’. A third participant emphasized 
the necessity of a genetic counsellor or trained genetics expert to be involved in this 
testing process, ‘I think a genetic counsellor is somebody who really does know genetics. 
I think more specific knowledge, I think, is very important. Because genetics is very 
confusing…’. Conversely, many individuals thought that this test could potentially be 
provided by their family doctor. One participant stated, ‘So I think the obvious place 
would be the family physician right, like I mentioned …a person has that trust factor 
hopefully with their doctor and, you know, in terms of around getting that test out to 
people….’ Another participant noted, ‘….should be a discussion that you should have 
with your family doctor, and all family doctors should be prepared on how to deal with 
this type of testing, with the questions from the patients, with the results’. Many 
participants thought that this future polygenic might be beneficial if publicly available, 
however certain concerns such as public education, cultural concerns, personalized 
service, and possible online accessibility would need to be addressed. One participant 
noted, ‘…public education a no-brainer, like I - you know if you'd have forums in 
different parts of the province where people could come and just, you know, have a Q&A 
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and a bit of a presentation or people could go online and log in. I think I might do a few 
different venues, I think I might have like kind of a town hall thing where the 
professionals come and they explain what would go on and that sort of thing. For those 
people who couldn't get out to a town hall or something they could go online and maybe 
participate in a webcast or something; God with technology now there's so many options 
right’. Another participant emphasized education for family doctors, ‘…I do think the 
education component would be important, you know, making sure the doctors, even if 
they're not genetic counsellors have a sheet or some information or a website to refer 
people to that explains in basic terms what the testing is’. One participant emphasized, ‘I 
think a personal interaction is better because, you know, sometime we can read things on 
the net that we shouldn’t interpret them differently. I think it's better to have one face to 
face so that you can ask questions if you have them’. Lastly, one participant emphasized 
cultural needs, ‘…Medical information is something that is personal but it's also a tool for 
having a long and healthy life. I think some ethnic groups have more trouble with trusting 
doctors …And how to get it across in multiple languages in Ontario…getting it across to 
a language group as well to older women who have not worked outside the home and 
never got comfortable with English’.  
Miscellaneous Themes 
One participant brought up the point of the utility of other parts of the genetics 
assessment (ie. risk models) as having influenced her medical treatment for breast cancer. 
She stated, ‘… the results also came back with a calculation of my risk of developing a 
new primary breast cancer, so the breast that is currently not affected. So that is definitely 
– you know, the probability of that, of a new primary cancer, certainly is impacting my 
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decision in terms of moving forward with a mastectomy – a double mastectomy or not, so 
it is very relevant’.  
 
 Many participants talked about how they delivered the news of their GPT results 
to family members and their family members’ reactions to the news. An affected 
individual who tested negative stated,  ‘…it went well, and I think they also were worried 
about the results. I think the whole family was concerned about this, and knowing the 
genetic results was very important for all of us. And we knew that there was a bit of risk 
on both sides of the family, so for us in particular, it was very important to know the 
results’. An unaffected individual who tested positive for a BRCA2 mutation stated, ‘Well 
they were both upset which then made me more upset. But my husband's very like, 
typical. Typical man I'd say. Okay, well this is the problem, we're going to fix it this way, 
what do you have to do kind of thing’.  
 
  A few participants highlighted the importance of having a genetic counsellor 
apart of their GPT experience. One individual stated, ‘I think having the genetics 
counsellor in the clinic itself, is fantastic. I don’t know if that’s standard process across 
most hospitals or not, or if your study is even going to have any kind of influence on that 
sort of thing, but absolutely, I mean, the fact that the genetic counsellor is in my breast 
clinic, is available on a daily basis, is able to be flexible enough to come and talk to me, 
you know, while I'm getting chemotherapy, explain the results, that sort of thing, I mean, 
that makes all the difference. Because if it wasn’t that easy, I probably would have, you 
know, maybe delayed it more, or not taken it as seriously…’ Another individual 
explained, ‘… I do want to mention that I had a great time and a positive experience 
talking with my counsellor. I think she did a great job of explaining to me more or less 
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everything, asking the right questions and trying to understand my situation, my family 
history, and trying to understand more about myself and how I developed this cancer. She 
was very empathic – I think empathy was an important thing to me, the fact that you are 
not just seen as a number, but a patient with an issue, and this is something extra that is 
helping you. That, I think, was great – we had a good time with her’.  
 
 Some patients indicated that they had done their own research either before or 
after the GPT consultation. One unaffected participant stated,  ‘I had done some research 
on this before and even though my mom hadn't had breast cancer the fact that I got it so 
young I think that’s one of the markers for a genetic mutation... ‘ 
 Based on their GPT results, some affected participants who tested negative now 
believe that their cancer may have been due to alternative causes. One woman stated, ‘…I 
have my own faith, and so to me, this was really kind of an indication that, you know, 
this was an act of God and this has to do with the path I am to walk in my life, and to 
some extent, that is comforting to me, to know that this is for a reason, and it’s not just 
science gone amuck…And for me, I justify it as saying, okay, this is something 
purposeful and there must be something I'm to learn from it, so … whereas other people 
might take comfort knowing, okay, this is just genes, genetics and there’s nothing I could 
do and ya-da-ya-da…’ Another participant explained, ‘Yeah, the family history is 
important, it's a part of the whole story. In my case, the use of patches and birth control 
pills for over twenty years… So yeah, it’s been a long time using steroids, you know, so 
birth control, weight control. That, I think is a huge risk…the fact that I smoke for over 
fifteen years or so, that also had an impact…The lifestyle, the food – I take a lot of red 
meat, sausages, packaged ---. So a few things. I'm not doing as much exercise as I should 
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do, so there are so many factors that I think that have been involved. But for sure, one of 
those was – yeah, the steroids and the hormones’. In another case, a woman who tested 
positive for a CHEK2 mutation originally thought her family history of cancer had 
alternate causes but her GPT results changed that, ‘…through the chemicals my mom 
used when she did roses for 20 years, before they stopped the poisons and 
stuff. [Interviewer:    So you felt maybe the cancer might have been a result of 
that.] Yeah…’ 
 A couple of participants expressed anxiety in regards to waiting to receive their 
GPT results. One woman indicated, ‘… every day was just like you’re trying to - I don't 
think I've done so much yoga in my life but anyways, yeah it was definitely stressful 
because as I said I thought because of my age and, you know, maternal breast cancer I 
thought that the dice could, you know, not be in my favour here; and then I would be 
upset that I had waited so long and had, you know, done that earlier for my daughter’. 
 Some participants who did not receive VUS results were asked their opinions on 
how they would have felt had they received an uncertain result from their GPT. One 
participant indicated, ‘I didn’t receive any inconclusive results but the thing is just I do 
think there's value in it…it’s better to be proactive about it than not being proactive about 
it…So I think that if something had come back inconclusive it would have just indicated 
that I'm not safe. It could be … maybe a recommendation to test again in a few years, but 
it actually - I think that from the way I think about things I think that, you know, it’s a 
cautious approach to things …and then you could start looking at well is there anything I 
can do, you know. It could reinforce how I handle my diet, exercise or whatever it is. But 
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I think there is value in knowing what an inconclusive results means to a person because 
prior to that I thought that inconclusive would mean…’ 
 Two participants who did not receive VUS results still felt as though there was 
some uncertainty. One participant who tested positive for a CHEK2 mutation stated, ‘… 
it wasn't definitive. It's not saying I'm definitely going to get colon cancer in six months. 
It's just there is a predisposition to colon cancer in my genetic background. There you 
go. So it's still an if, and, or maybe. Not a definitive’. Another participant who was 
affected by breast cancer but tested negative felt there was still uncertainty as to what 
caused her cancer, ‘…Like I said there's always there million dollar question why did this 
happen to a healthy 34 year old female right’. 
 Some participants used the phrase ‘the more the better’ or similar. There was also 
an underlying theme of knowledge is power; that they participants felt empowered by the 
information that they received as a result of this test. For example, one participant who 
was affected by breast cancer but tested negative stated, ‘…being diagnosed with breast 
cancer I find that I think if it come back positive it would have - I would have been 
prepared for what's to come … it’s information right and information is power so I think 
that having an answer even if it's not a favourable answer, you know, forces you to move 
forward in one direction…’ Most participants who were asked explicitly whether they 
prefer to have more information rather than less in life situations replied that this was true 
for them.   
 
Discussion   
Over the past 20 years, genetic testing for breast cancer susceptibility has centred 
around BRCA1/2 analysis. The discovery of additional genes involved in breast cancer 
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susceptibility coupled with cheaper and faster analyses has lead to the production of gene 
panel tests. This has led to increased rate of not only mutation detection, but also an 
increase in VUS results. Currently, most risk assessment centres in the province of 
Ontario are using or contemplating using GPTs as the routine genetic analysis in 
individuals who meeting criteria for what was once only BRCA1/2 analysis. Most of this 
change to GPT has been carried out within the same established protocols of genetic 
counselling in high risk clinics as it has been with BRCA1/2. For example, patients who 
test negative or receive a VUS result from GPT are still assessed for future breast cancer 
risk using risk-modeling software.  It is within this context that we asked participants of 
their experiences with the provision of GPT. 
 Presently, more and more individuals are seeing GPT and cancer risk assessment 
as the ‘next step’ in either their cancer care process or in their quest to find out why they 
have a personal or family history of cancer. Many individuals are keen on being prepared 
for potential future health risks and want information on how to prepare for and/or 
mitigate these risks.  
Our research suggests that issues surrounding GPT closely resemble issues 
encountered during traditional single-gene genetic testing. One of the main issues in GPT 
is pre and post-test counselling for VUS and negative test results. Patients should be 
advised that a negative GPT result does not return them back to population risk for future 
cancers, nor does it preclude them from having a mutation in a gene that was not included 
in the panel or has not yet been discovered. Other issues surrounding GPT include testing 
positive for a mutation that confers risks for additional types of cancers (some of which 
may not be screenable) and implications for family members if a mutation is found.  
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 Participants were generally pleased with the provision of this test and the pre and 
post-test counselling that they received. However, some of the opinions collected during 
this research suggest that while patients are interested in having a lot of information 
regarding their GPT pre and post-test, perhaps this information should be better tailored 
to the patient’s preference and/or education level. Additionally, some participants wished 
that there was a shorter turnaround time for results.  
Participants that received VUS results generally indicated that they had a good 
understanding of these results and the subsequent clinical implications (i.e. screening and 
management are to based on personal/family history of cancer). Furthermore, most 
participants indicated that these results did not cause much stress or strong emotional 
reactions. These individuals did not seem to be very concerned or anxious regarding their 
result, however some acknowledged that uncertainty is not handled the same by everyone 
and that this should be taken into consideration when carrying out GPT. Some 
participants took comfort in that one day uncertain results (ie. VUS results) might be 
elucidated, as more data is gathered. Given these findings, one might infer that patients 
are generally capable of understanding an uncertain result and would fare similarly if 
uncertain results were to arise in future genetic tests.  
Overall, GPT appears to be well-tolerated within the context of a traditional 
genetics assessment. Participants generally had positive feelings in regards to their 
experience receiving GPT and felt that they would recommend the process to others in a 
similar situation. 
 From the inception of breast cancer genetic testing with BRCA1/2 analysis, to the 
introduction of GPT within the context of a cancer risk assessment, we are now faced 
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with the advent of polygenic genetic testing via whole exome, whole genome, or SNP 
platforms (Li et al., 2017). SNPs, or single nucleotide polymorphisms, can be relatively 
common in the general population and individually may not mean much, but when 
combined may carry an additional risk for breast cancer. Recently, many of these SNP 
tests have been validated however there has yet to be a widespread implementation of this 
testing within the framework of a routine cancer risk assessment.  
Responses from the participants in this study suggest that they would be willing to 
take the next step into receiving genetic testing via these new technologies and are not 
too concerned by the uncertainty that it might provide. There was a general consensus 
among participants that did not receive a clinically significant result through GPT that 
they would be open to pursuing future polygenic testing that looked at more genetic 
elements than GPT, despite the possibility of again receiving an uncertain result. 
Motivating factors for pursuing these tests resembled motivating factors for pursuing 
GPT. Participants also seemed open to finding out information regarding diseases other 
than cancer, however some individuals had reservations about learning about diseases for 
which there is no cure or screening available.  
In the future, there is the potential that all females may be offered this polygenic 
test to determine proper levels of screening for individuals in the population regardless of 
their familial cancer risk. In other words a more personally stratified assessment of breast 
cancer risk regardless of any existing family cancer history. Participants found value in 
this proposition but also had mixed responses as to whether this future polygenic testing 
should be provided through their hospital, a specialty breast clinic, genetic services or 
their family doctor. Many acknowledged the possible burden to these communities and 
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agreed that widespread uptake of polygenic testing could take place as part of a 
Provincial program that is used for population screening such as the Ontario Breast 
Screening Program. If the provision of this test was to fall under the typical scenarios that 
single gene and GPT currently are, issues such as education of providers and the general 
public, cultural considerations, and the availability of a genetic counsellor or specialist to 
personally answer questions or concerns would need to be addressed.  
Study Limitations 
 Study participants were recruited based on their history of receiving genetic 
testing at the Marvelle Koffler Breast Centre at Mount Sinai Hospital. As a result, the 
opinions are reflective of the genetic counselling process at this specific hospital. While 
one might hope that these opinions would be representative of patients’ experiences at 
genetic testing clinics across the province of Ontario, this may not truly be the case. 
Furthermore, study participants were only those who proactively returned the study 
consent form to indicate their interest in study participation, or individuals who agreed to 
participate after being contacted by phone.  It is possible that certain opinions were 
missed based on who was recruited for the study, such as participants who received 
secondary findings as a result of the test or participants who had negative opinions 
regarding GPT and thus were uninterested in participating in the study. Also, although we 
interviewed to beyond thematic saturation, we have only interviewed a small number of 
clinic participants. It is also possible that people self-selected for those who had a good 





 Data obtained during the course of this research study may have implications on 
future genetic testing and genetic counselling practices in Canada. Understanding the 
underlying motivations and experiences of individuals who underwent GPT is critical to 
providing support during the cancer genetic counselling session.  
 Additionally, this research will inform future polygenic testing. Given the positive 
reception that GPT received during the course of this study, genetics clinics may be more 
open to offering more complex, polygenic testing to patients in the near future.  
Conclusions & Future Directions 
 The data suggests that GPT is well-tolerated within the context of a traditional 
genetics assessment and that individuals would be open to pursuing future polygenic 
testing within this framework to help answer the question as to why they developed 
cancer or have a family history of cancer. Further quantitative research would provide 
robust data on whether a larger population of individuals would be open to this more 
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Appendix - 1:  
Interviewee demographic characteristics 
Characteristic N = 14 
Mean age in years (range) 47.6 (32 – 68) 
  
Race/Ethnicity  
Non-Hispanic White 5 
Ashkenazi Jewish 2 
Hispanic 3 
Aboriginal 1 
Mixed Ethinicity – 
Indian/Pakistani/Irish/Scottish/Welsh 
1 





Marital Status  
Married 8 
Never married 5 
Divorced/Separated/Widowed 1 
  
Gene panel test result  
Positive 3 [ATM, CHEK2 & BRCA2] 
VUS 4 [ATM, PALB2, MLH1 & MLH1] 
Negative 7 
  













Appendix – 2: Interview Questions 
Developed by Gord Glendon, MSc. 
Introduction 
o Hello, may I please speak to X. 
o This is X calling from the, Understanding Gene Panel Testing study for our 
scheduled interview. Thank you for taking my call. 
o As a reminder, we will be audio taping this interview and then transcribing it into a 
word document. This is so we can later explore the details of what we have discussed 
today. Is that alright with you? Your transcript will be identified only by a number 
and will not contain any directly identifying information such as your name, address 
or date of birth.  
o If there is any topic or question you don’t want to talk about for any reason, just say 
‘skip’ and we will move onto another question. 
o Please feel free to discuss anything you would like to with respect to your genetic 
counselling and testing experiences. This interview is the forum for you to speak your 
mind and there are no right or wrong answers. 
o Please keep in mind that we cannot give you any medical advice or answer any 
questions about your results. 
o A typical interview of this type could last up to 30 to 45 minutes. 
o Are you ready to go ahead with the interview now? 
 
Understanding the participants GPT experience: Defining the timeline and type of 
testing 
 
We understand that you have been seen in the Familial Breast Cancer Clinic at the 
Marvelle Koffler Centre for a risk assessment within the last year. We also understand 
that you had a genetic test or tests there. We would like to talk to you about how that 
process took place.  
 
Ø Can you walk us through your risk assessment process? Did you receive 
genetic counselling and then testing? Did you have 2 separate tests (one 
for BRCA1/2 and one called a gene panel test)? 
 
Ø Do you know what the test you had is called (prompt for GPT)? 
 
Ø Can you explain to me what the GPT is? Is it a blood test? What does it 
look for? Is it different from the first blood test you had (BRCA1/2)? Does 
it look at more than one gene at a time or only one?  
 
Ø Did you receive the results from the genetic testing you had? If you did 
would you mind sharing them with us to help us better understand the 
impact the testing may have had on you? 
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Ø How were the results communicated to you? Were results delivered by the 
genetic counsellor or the physician or both? Was it over the phone or in 
person? Did you bring someone with you or were you alone for the results 
session? Did you have a follow up session with the genetics team after the 
results session? 
 
Ø How long was the process from the time of giving blood to getting the 
results? 
 
Impact of GPT for participant 
 
We know that having genetic testing can sometimes lead to results that have a direct 
effect on our health, especially when the results are positive. Even the experience of 
having a negative genetic test, without getting a clinically significant result can have an 
effect for some. Now, we would like to hear what impact, if any, did undergoing the GPT 
have for you and possibly your family? We are interested in both how it may have 
impacted your thinking and feelings as well as any impact it may have had on your health 
behaviours such as screening, surgeries. Also did your results have any effect on other 
family members if any (siblings, children, parents) 
 
Ø What were you told your result means in terms of your risk for breast 
cancer? What were you told the results mean with respect to the cause of 
your cancer? What were you told the results means with respect to your 
family’s history of cancer? 
 
Ø Do you feel that the GPT helped to explain your personal or family history 
of breast cancer? Do you feel the GPT added any information beyond 
what you may have learned from your BRCA1/2 test? Do you feel that 
this test added anything to your understanding of your cancer / your 
family’s cancer / your breast cancer risk? 
 
Ø Do you feel there was uncertainty in the results you received from your 
test? In other words, did you receive a result that may or may not explain 
your / your family’s cancer history? If so, how do you feel about that 
uncertainty? Does receiving this uncertainty make you feel worse, better 
or no different than before the test / after the BRCA1/2 test? 
 
Ø In general, what are your feelings about your GPT results? Do the results 
give you peace of mind / cause you to worry more about breast cancer risk 
/ not change how you feel about breast cancer?  
 
Ø Have you told anyone about having the GPT? Results? Why or why not? 
 
Ø Did you receive a specific course of action or screening recommendations 
after getting your GPT results? Did this course of action / screening 
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recommendation change from what you had been recommended 
previously?  
 
Ø Do you think that you will change any of your health behaviours or cancer 
screening based on the information you received in this test? Is there any 
health behaviour you have wanted to change that the test result will help 
motivate you to carry out? Do you feel that possibly changing aspects of 
your lifestyle like diet, exercise or screening could affect your chance for 
developing cancer? 
 
Opinions and Preferences on the Provision of GPT 
 
Now that you have gone through the process of GPT, we would like to hear about your 
opinions and preferences for how the test should be delivered. This test is new in Ontario 
and any feedback you have can be extremely valuable.  
 
Ø Now that you have received your results, do you think, in retrospect, that 
you had a good understanding of the possible results you could get from 
the test (no increase in cancer risk to moderate increase to high increase)? 
Do you feel that you had a good understanding of the complexity of the 
test before you received your results? Do you feel you had a good 
understanding of the wide range of clinical recommendations you could 
get from the results of this test (from no change in screening to slightly 
modified screening to frequent screening with a discussion of prophylactic 
measures)? 
 
Ø What would you change, if anything, about your preparation for the test? 
Would you prefer more, less or the same amount of pre-test information? 
Are there specific things that, in retrospect, you would have liked to know 
more about? Did you feel that there was too much information presented 
to you before the test, not enough or just the right amount? 
  
Ø What would you change, if anything, about the process of receiving results 
from this kind of test? Would you have liked more or less detailed 
information about the results? What was your opinion on the patient letter 
that was sent to you after the test? Do you feel like it helped reinforce your 
results, or were you left with a greater sense of confusion?  
 
Ø Do you feel there’s any benefit to receive test results that have no clear 
implication for cancer risk or clinical management? Do you have an 
opinion about the usefulness of receiving results with uncertain 
significance?  
 
Ø If you received results of unknown significance, you were likely told that 
these results are typically re-classified over time and you were asked to 
keep in touch with your genetics clinic every few years to see if your 
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results have been re-classified. Would you prefer to be responsible for 
contacting your clinic regarding any changes in classification, or you 
would you prefer to have the clinic automatically contact patients instead? 
 
Ø Would you recommend this test to others? Would you recommend this test 
to others in your family? 
 
Ø In general, what is your opinion of GPT? Are there aspects of the test that 
you would not advocate for? 
 
Ø Is there anything else you would like to discuss with respect to your 
opinions or preferences for the delivery of this test? Is GPT something that 
genetics clinics should continue to offer? 
 
Future Polygenic Test 
 
Understanding the genetic causes of familial breast cancer is constantly evolving. You 
have gone through the first 2 generations of genetic testing. The first test looked at 
BRCA1/2 genes. The second is GPT which examines another 20 or so genes associated 
with familial breast cancer. Just over the horizon is another group of tests that will look at 
a much larger part of the human genome to try and understand how cancer runs in 
families. The techniques will vary but the underlying idea is that we will be able to look 
at thousands of genes at the same time and something called SNPs. Individually, these 
elements may not mean much, but together they will give us a much more complete 
picture of breast cancer risk. You may have heard of whole genome sequencing which is 
an example of this. The promise of these tests is that they may be able identify someone’s 
cancer risk from very low to very high allowing better screening and treatment, but also 
your risk to develop other diseases. We would like to get your reaction to such a possible 
test.  
 
Ø If this test was available as I described it, would you be motivated to have 
it? Why or why not? Was there anything in your experience with GPT that 
would make it more or less likely to be interested in this type of more 
comprehensive test? 
 
Ø If this test had a possibility of giving a result of uncertain clinical 
usefulness, would that make you more or less likely to pursue it? Why or 
why not?  
 
Ø It is possible that such a test could also reveal risks for diseases other than 
cancer. If this was the case, would you like to know about those other risks 
as well? Why or why not? Do you think that if you have a test for cancer 
risk, the results should be strictly related to cancer or include risks for 
other diseases? Would you want to know about results that show that you 




Ø If a company provided this test directly to the public, outside of the 
medical system, and was reasonably priced, would you consider having it? 
Why or why not? Do you feel that these types of tests should be provided 
only by a doctor in an established medical setting to patients who meet 
criteria for testing, or be available to anyone who wants to have it and is 




Thank you very much for talking with us today. Your thoughts and suggestions are very 
valuable in helping health professionals to provide the best possible service going 
forward. 
 
Ø Do you have anything else you would like to discuss with respect to GPT? 
Feel free to comment on anything we discussed earlier or anything we 
didn’t cover that you may feel is important. 
 
Ø Thanks again for your contribution. 
 
 
